See how Dr, Nilson from QIAGEN Digital Insights navigates an interesting intersection of the tumor microenvironment, mutation status, and gene expression to identify plausible activators affecting bevacizumab targets in low-grade glioma.

In this webinar participants will learn about

• The tools used to identify key genes in LGG
• How we choose specific gene alterations
• The intersection between immune response tumor mutations
• How we identify other key genes of interest 
• How we build a network tying all these elements together